PATENT CLAIM ANALYSIS

Application Number: 15869549
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "195000"]

Abstract:
This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.

Claim (Index 5):
A method for producing an active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof, comprising the steps of:\n (a) culturing a Chinese Hamster Ovary (CHO)-derived END3 complementation group cell or derivative thereof; (b) preparing a first mammalian expression vector capable of expressing said active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof in said END3 complementation group cell or derivative thereof; (c) preparing a second mammalian expression vector capable of expressing recombinant human sulfatase modifying factor 1 (SUMF1) or biologically active fragment, mutant, variant or derivative thereof in said END3 complementation group cell or derivative thereof; (d) transfecting said END3 complementation group cell or derivative thereof with said first and second expression vectors; (e) selecting and cloning of a transfectant of said END3 complementation group cell or derivative thereof that expresses said active highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof; and (f) optimizing a cell culture process method for manufacturing said highly phosphorylated recombinant human lysosomal sulfatase enzyme or biologically active fragment, mutant, variant or derivative thereof, wherein the recombinant human lysosomal sulfatase enzyme is selected from the group consisting of arylsulfatase A (ARSA), arylsulfatase B (ARSB), iduronate-2-sulfatase (IDS), sulfamidase/heparin-N-sulfatase (SGSH), N-acetylglucosamine-sulfatase (G6S) and N-acetylgalactosamine-6-sulfatase (GALNS).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.58537
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12355453', '14281538', '13188907', '14573907', '14924405']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7325414822421005
- 35 USC 102 Novelty (BERT): 0.6967454808082055
- Combined Prediction Score: 0.7289618820987109
- Mean Citation Score: 709.8492980000003
- Max Citation Score: 756.8287
- Similarity Product: 712.747164818418

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test